Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | Visiongain Reports | The Anti-Migraine Market 2007 to 2022

The Anti-Migraine Market 2007 to 2022

Migraine is a serious neurological disorder characterised by recurrent headaches, varying in severity and frequency. Accounting for the loss of over 100 million working days in the US alone, the economic cost and social impact of migraine is significant. Furthermore, the people most susceptible to migraine are those within their most productive years (22-55), causing both personal and professional disruptions and a significant burden on healthcare services.

This in-depth management report examines the prospects for anti-migraine drugs from 2007, right through till 2022. It delivers sales forecasts for the leading pharmaceutical products, so that you can analyse your pipeline and market. The market for anti-migraine drugs is the slowest growing segments in the pain management market with a CAGR of 0.11% for the period 2006-2012. However this slow growth will be due to the 2009 patent expiry of the leading product in the market.

Nevertheless, visiongain predicts that with a high prevalence of migraine, the success of newer triptans and the launch of new therapies, the market will expand further beyond 2012, generating revenues of $5268m in 2022, increasing CAGR for the period 2006-2022 to 2.7%. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

The Anti-Migraine Market 2007 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Anti-Migraine Market concentrates on the following essential aspects of the market:

• Discussion of the current pharmaceutical market

• Forecast of the worldwide pharmaceutical market from 2007-2022

• Drivers and restraints facing the anti-migraine market

• Opportunities and threats facing the anti-migraine market

• Growth of the anti-migraine sector between 2007-2022

• Commercial prospects for the market-leading drugs, with sales forecasts from 2007-2012

• The potential of generics manufacturers to penetrate this market

• Pipeline developments with blockbuster potential

• Currently marketed drugs with blockbuster potential

• Discussion of unmet therapeutic needs and relative advantages of products

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for anti-migraine drugs from 2007-2012

• To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2007-2012

• To determine key activities of leading companies

• To discover “hot” pipeline developments and up-and-coming products

• To determine the forces that influence the market for anti-migraine products:

• Competitive characteristics of the market

• Drivers

• Restraints

• Strengths, weaknesses, opportunities and threats (SWOT analysis)

• To find out where the anti-migraine market is heading - both technologically and commercially

The report provides in-depth market analysis upon these areas, and extensively identifies both prescription and OTC drugs. The report also focuses on the technological issues, including the latest trends, patents, new products and other influential factors. The study also assesses the challenges faced by companies in the pain industry, and what exciting market opportunities exist in this up- and-coming therapeutic area.

Why You Must Buy This Report?

This report features news, insights, the latest developments and an in depth survey of the pain market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company 'the edge' on your competitors. You can not afford to be without this latest report from visiongain.

Unique benefits to you when you order this report

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Full searchable report when you buy the company or corporate editions

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

Publication date: 13-11-07

No of pages: 76
Table of Contents

Price

Single Use Licence $2500.00

Department Licence 5 Users $5000.00

Company-wide Intranet Licence $8750.00

Company over 2500 employees $11750.00

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions